| value |
{"aggregator_url":"https://www.sec.gov {"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1438133/0001438133-26-000034.txt","as_of":"2026-04-08T19:57:42.365437+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1438133/0001438133-26-000034.txt","company":"TANDEM DIABETES CARE INC","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1438133/0001438133-26-000034.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_32739722273c4502","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1438133/0001438133-26-000034.txt","content_type":"text/plain","enriched_at":"2026-04-09T01:38:55.535489+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"tndm-20260407","final_url":"https://www.sec.gov/Archives/edgar/data/1438133/0001438133-26-000034.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1438133/0001438133-26-000034.txt","source_event_id":"evt_4f73a86c9b1d","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"DEF 14A","fp":"24ce96ded862633e","kind":"sec_filing","published_at":"20260407","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.86,"dates_mentioned":["2026-04-07","2025-12-31","May 20, 2026","2027 annual meeting of stockholders","December 31, 2026"],"entities":[{"asset_class":"equity","name":"Tandem Diabetes Care, Inc.","relevance":"high","symbol":"TNDM","type":"issuer"},{"asset_class":"other","name":"Ernst & Young LLP","relevance":"medium","symbol":"","type":"auditor"}],"event_type":"listing","information_gaps":["What specifically changed versus a prior known state is not provided in the signal text (no prior DEF 14A version or delta details included).","The proxy statement\u2019s detailed descriptions for each proposal (e.g., exact plan share increase amount, exact charter amendment language, and director nominees) are not included in the provided excerpt.","No financial guidance or financial implications (e.g., earnings, revenue, cost outlook) are stated in the provided text; only meeting agenda items are shown."],"key_facts":["SEC filing type: DEF 14A (definitive proxy statement).","Issuer: Tandem Diabetes Care, Inc. (TNDM).","Filed as of date: 2026-04-07; conforming period of report: 2025-12-31.","Annual meeting notice: Wednesday, May 20, 2026 at 3:00 p.m. Pacific Time.","Meeting format: held virtually by live internet webcast at www.virtualshareholdermeeting.com/TNDM2026.","Stockholder matters listed: (1) elect nine directors for one-year terms expiring at the 2027 annual meeting.","Stockholder matters listed: (2) non-binding advisory approval of named executive officers\u2019 compensation.","Stockholder matters listed: (3) approve the Company\u2019s 2023 Long-Term Incentive Plan, as amended, including increasing shares authorized for issuance under the plan.","Stockholder matters listed: (4) approve an amendment to the Amended and Restated Certificate of Incorporation to provide for removal of directors with or without cause, as required by Section 141(k) of the DGCL.","Stockholder matters listed: (5) approve an amendment to limit liability of officers to the maximum extent permitted by Section 102(b)(7) of the DGCL and implement other DGCL-related changes.","Stockholder matters listed: (6) ratify Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.","Payment of filing fee: No fee required (per the proxy statement header)."],"numeric_claims":[{"label":"Annual meeting date","value":"May 20, 2026"},{"label":"Annual meeting time (Pacific)","value":"3:00 p.m."},{"label":"Number of directors to elect","value":"nine"},{"label":"Director term length","value":"one-year term"},{"label":"Fiscal year end for auditor ratification","value":"December 31, 2026"},{"label":"Filing date (as of date)","value":"2026-04-07"},{"label":"Conforming period of report","value":"2025-12-31"}],"primary_claim":"Tandem Diabetes Care, Inc. filed a DEF 14A definitive proxy statement on 2026-04-07 for its annual meeting scheduled for May 20, 2026.","relevance_score":0.55,"sentiment":"neutral","source_quality":"high","summary":"Tandem Diabetes Care, Inc. filed a definitive proxy statement (DEF 14A) for its 2026 annual meeting of stockholders. The filing sets the meeting for May 20, 2026 and lists seven matters for stockholder approval, including director elections, advisory executive compensation, and several governance/plan proposals.","topics":["SEC filing","proxy statement","annual meeting","corporate governance","equity compensation plan","director election","executive compensation advisory vote","auditor ratification"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form DEF 14A \u00b7 TANDEM DIABETES CARE INC \u00b7 Filed 20260407","ticker":"TNDM","tickers":["TNDM"],"title":"TNDM filed DEF 14A","url":"https://www.sec.gov/Archives/edgar/data/1438133/0001438133-26-000034.txt"}... |